Crispr Theraptc (CRSP) Given Daily Coverage Optimism Score of 0.11
Press coverage about Crispr Theraptc (NASDAQ:CRSP) has been trending somewhat positive recently, according to Accern Sentiment. The research firm scores the sentiment of press coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Crispr Theraptc earned a daily sentiment score of 0.11 on Accern’s scale. Accern also gave news articles about the company an impact score of 42.4576727324962 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
Here are some of the news articles that may have impacted Accern Sentiment Analysis’s rankings:
- Crispr Theraptc’s (CRSP) “Buy” Rating Reiterated at Barclays PLC (americanbankingnews.com)
- Zacks: Analysts Anticipate CRISPR THERAPTC (CRSP) Will Post Quarterly Sales of $2.05 Million (americanbankingnews.com)
- -$0.60 Earnings Per Share Expected for Crispr Theraptc (CRSP) This Quarter (americanbankingnews.com)
- Insider Selling: Crispr Theraptc (CRSP) CEO Sells 18,470 Shares of Stock (americanbankingnews.com)
Crispr Theraptc (NASDAQ CRSP) opened at 19.15 on Tuesday. The firm has a 50-day moving average price of $18.56 and a 200 day moving average price of $17.82. Crispr Theraptc has a 52-week low of $11.63 and a 52-week high of $25.00. The stock’s market capitalization is $777.32 million.
Crispr Theraptc (NASDAQ:CRSP) last issued its quarterly earnings data on Thursday, August 10th. The company reported ($0.56) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.62) by $0.06. The firm had revenue of $3.60 million during the quarter, compared to analysts’ expectations of $3.29 million. Crispr Theraptc had a negative net margin of 406.61% and a negative return on equity of 47.46%. Crispr Theraptc’s quarterly revenue was up 350.0% compared to the same quarter last year. On average, equities research analysts predict that Crispr Theraptc will post ($2.43) EPS for the current year.
Several research analysts have commented on the company. Barclays PLC reissued a “buy” rating and issued a $29.00 price objective on shares of Crispr Theraptc in a research report on Friday. Chardan Capital reissued a “buy” rating on shares of Crispr Theraptc in a research report on Monday, August 14th. Oppenheimer Holdings, Inc. reiterated a “market perform” rating on shares of Crispr Theraptc in a research report on Tuesday, July 18th. Cann assumed coverage on Crispr Theraptc in a research report on Monday, July 17th. They issued a “market perform” rating on the stock. Finally, SunTrust Banks, Inc. assumed coverage on Crispr Theraptc in a research report on Thursday, July 13th. They issued a “hold” rating and a $16.00 price objective on the stock. Four analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $23.08.
In other Crispr Theraptc news, insider Tyler Dylan-Hyde sold 15,000 shares of the business’s stock in a transaction on Tuesday, August 8th. The shares were sold at an average price of $18.57, for a total transaction of $278,550.00. Following the completion of the transaction, the insider now owns 167,727 shares of the company’s stock, valued at approximately $3,114,690.39. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Rodger Novak sold 18,470 shares of the business’s stock in a transaction on Tuesday, September 5th. The stock was sold at an average price of $20.76, for a total transaction of $383,437.20. Following the transaction, the chief executive officer now directly owns 1,148,007 shares of the company’s stock, valued at approximately $23,832,625.32. The disclosure for this sale can be found here. In the last three months, insiders have sold 827,921 shares of company stock valued at $15,063,254. Company insiders own 39.98% of the company’s stock.
Crispr Theraptc Company Profile
Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell.
Receive News & Stock Ratings for Crispr Theraptc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Theraptc and related stocks with our FREE daily email newsletter.